“People are the heart of Grifols, and we want everyone to feel involved in the company’s journey moving forward,” mentions Raimon Grifols, Co-CEO, Grifols. Companies, physicians, and lab technicians specializing in the field of haematology are in high demand as medical science continues to move ahead through its journey to finding cures for some of the world’s deadliest diseases. The utilization of advanced technology to analyze blood cells to see new techniques to heal patients with a terminal illness has given a reason for professionals in the medical science arena to believe in the future of drug production. For over sixty years, Grifols, a MedTech service provider and supplier, is committed to understanding and creating high-quality products that magnify the health and well being of people globally. Patients want the most effective treatment plans and quick diagnosis of the nature of their ailments. The team at Grifols is attentively listening to their clients about patient conditions to ensure that people undergoing therapeutic procedures are receiving the best possible attention. The company has four main divisions— bioscience, diagnostic, hospital, and bio supplies—through which they conduct top-grade research and development to offer a broad umbrella of innovative medical products and services.
One area in which Grifols excels in is diagnostics; the company has an Immunohematology Center that partner with medical treatment facilities to solicit patient care through an in-depth analysis of clinically relevant blood group systems. The facility offers Grifols’ clients a chance to make their laboratories more productive, and deliver industry standard treatment plans by leveraging the advanced blood checking capabilities at Grifols’ CLIA reference laboratory. It saves hospitals and clinical diagnosis centers a lot of time and assets that would otherwise be absorbed by the sophistication of the blood tests being done manually.
Typically, clinical diagnosis results of the tests can take up to 10 days, depending on the condition to be evaluated. Grifols deploys a unique assay creation service that not only reduces the time it takes to get a diagnosis from the lab to a physician it also can be made available to check even distinctive disease cases. It allows users access to an extensive array of serological, and molecular tests as well as rare red blood cells, antibodies and molecular variants from across the world. The firm makes it easy for clients to access their services by providing round-the-clock telephonic support.
Clients of Grifols leveraging the Immunohematology Center are treated to tools and services that help them take the best precautionary measures against alloimmunization and reactions to blood transfusions. In the neo-natal sector of medical science it helps counter hemolytic disease of the fetus and newborn and mitigates the issue of unwarranted administration Rh immune globulin. Since Grifols is in contact with a lot of patient data from clients, it was able to create an expansive and deeply categorized blood donor database that includes donors for even rare blood types. Besides, the exemplary reference services that Grifols’ provides, it has a long list of reference lab tests that it performs. Some of the tests they conduct include ABO/Rh Discrepancy Resolution, Antibody Identification, and Genotyping for red blood cell antigens.
In a recent statistics report released by Grifols’, it was shown that the company has recorded a total revenue collection of EUR 4,487 million, and has achieved 9.2% operating growth while earning a net profit of EUR 597 million. In terms of expanding globally, the firm has entered a strategic partnership with Shanghai RAAS to boost the growth of its plasma-derived products and diagnostic solutions in China, and other Asian regions.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: